68 results about "Drug group" patented technology

The invention relates to the technical field of large models, and particularly provides a knowledge base-based medical scheme recommendation method, system and device and a storage medium, and the method comprises the steps: obtaining a first disease and a second disease, the priority of the first disease being higher than that of the second disease; generating weight values for drug attributes in a pre-constructed drug knowledge graph according to the user attention input by the front end; based on the weight values, a first medicine group corresponding to the first disease and a second medicine group corresponding to the second disease are inquired from the knowledge graph; and generating a recommendation scheme based on the drug property characteristics of the drug entities in the first drug group and the second drug group by using a pre-trained random forest model. According to the method, a multi-dimensional evaluation system is established through the drug attributes and the weight values, and the dynamic weight values adapt to individualized data of patients, so that differentiated recommendation is realized.

The invention discloses a method for testing the non-inferior performance of a new drug when curative effect data obeys partial normal distribution, aiming at the condition that the curative effect data obeys partial normal distribution, the non-inferior performance of the new drug is tested so as to determine the non-inferior performance of the new drug relative to a standard drug, and meanwhile, the reliability of a detection result is ensured. The method comprises the following steps: S1, acquiring drug curative effect data in clinical tests: in a three-arm non-inferior clinical test, based on drug curative effect indexes, respectively acquiring drug curative effect data of three groups of clinical test results of a new drug group, a standard drug control group and a placebo control group, the curative effect data obeying partial normal distribution; s2, probability calculation of first-class errors: in the three-arm non-inferior hypothesis test model, a frequency method or a Bayesian method is used to calculate the drug curative effect data of the three groups of test results to obtain the probability of first-class errors, and the probability of first-class errors is the probability of occurrence of a standby hypothesis H1 when an original hypothesis H0 is established; and S3, non-inferior determination of the new drug: if the probability of making the first type of errors is greater than a given reference value, determining that the new drug has non-inferior relative to the standard drug, and the reference value is a critical value which is given in advance and has clinical significance.

The invention discloses a key effect and a targeted intervention strategy of YTHDF1 in regulation and control of a hepatocellular carcinoma immunosuppression microenvironment. In the tumor-associated fibroblasts, YTHDF1 enhances the translation efficiency of OTUD5 mRNA through an m6A dependency mechanism, an up-regulated deubiquitination enzyme OTUD5 is directly combined with a tryptophan metabolic rate-limiting enzyme IDO1, ubiquitination degradation of the tryptophan metabolic rate-limiting enzyme IDO1 is inhibited, tryptophan is further driven to catabolism to generate kynurenine, regulatory T cell differentiation is promoted, and an immunosuppression microenvironment is formed. Spatial transcriptomics shows that YTHDF1 + CAFs and Tregs are significantly co-localized in tumor tissues and have metabolic interaction. Based on artificial intelligence virtual screening, it is found that a natural compound hesperidin can be specifically combined with a YTH structural domain of YTHDF1, an OTUD5-IDO1 signal axis mediated by the natural compound hesperidin is blocked, and the KYN level is remarkably reduced. Animal experiments prove that the tumor inhibition rate of combined treatment of hesperidin and anti-PD-1 is increased by 40% or above compared with that of a single drug group, and synergistic interaction is achieved by inhibiting Tregs infiltration and enhancing the activity of cytotoxic T lymphocytes.

The invention discloses a tumor targeting boron-containing Fe3O4-based nano-enzyme and a preparation method and application thereof, and belongs to the technical field of tumor treatment.The tumor targeting boron-containing Fe3O4-based nano-enzyme takes boron-10 doped Fe3O4 nano-enzyme as a boron-containing drug group and an enzyme activity center, and the surface of the tumor targeting boron-containing Fe3O4-based nano-enzyme is modified with a targeting group; the targeting group is chitosan-folic acid-polyethylene glycol. The tumor targeting boron-containing Fe3O4-based nano-enzyme has relatively strong selective enrichment capacity on tumor cells such as melanoma, shows good biocompatibility and low toxicity, and has relatively strong apoptosis induction and killing effects on the melanoma cells in boron neutron capture therapy; meanwhile, active oxygen free radicals can be generated in boron neutron capture therapy to generate an oxidative damage effect.

To accurately perform an audit of a medicine including a plurality of tablets.SOLUTION: A medicine audit device includes: a rotary disc 401 that rotates around a predetermined axis; a camera 501 that images a medicine placed on the rotating rotary disc 401; and an imaging / audit processing part that determines a type or the number of medicines imaged by the camera 501. In this case, for example, the camera 501 continuously images a plurality of medicine groups placed on the rotating rotary disc 401, and the imaging / audit processing part determines a type or the number of individual medicines in the medicine groups.SELECTED DRAWING: Figure 3

The invention provides lignan, and belongs to the technical field of medicines. According to the invention, a compound shown as a formula I and a compound shown as a formula II are extracted, separated and identified from schisandra chinensis oil for the first time, and the compound shown as the formula I and the compound shown as the formula II are superior to a positive drug group arbutin in the aspect of inhibiting generation of melanin of mouse skin melanoma cells (B16F10); an inflammatory factor release inhibition experiment research shows that the compound shown in the formula I and the compound shown in the formula II have relatively good activity in the aspect of inhibiting LPS-induced mouse mononuclear macrophage RAW264.7 from releasing IL-6 and TNF-alpha; in a skin irritation experiment, the schisandra chinensis non-saponifiable matter containing the compound shown in the formula I and the compound shown in the formula II is non-irritant to the skin of a white rabbit, and it is proved that the compound shown in the formula I and the compound shown in the formula II can be applied to preparation of whitening and anti-inflammatory products. Formula I; formula II.

The invention discloses a formula of a Chinese herbal medicine patch for activating blood and dredging meridians and collaterals. According to the invention, a distinct-level efficacy system is formed through a monarch, minister, assistant and guide compatibility theory of traditional Chinese medicines and a modern preparation technology. The monarch drug group is used for promoting blood circulation to remove blood stasis as a core and is matched with the channel-clearing and collateral-activating components of the ministerial drug group, so that local qi-blood circulation can be effectively promoted, and the meridian blocking state is improved. The traditional transdermal limitation is broken through by an intelligent permeation enhancing technology adopted by the adjuvant drug group, so that the drug components rapidly permeate into deep tissues and are continuously released, the advantage of overall regulation of traditional Chinese medicines is reserved, and the problem of low bioavailability of an external preparation is solved. The precise design of each component in spatial distribution and time release realizes quick-acting and long-acting dynamic balance, is particularly suitable for the requirements of different pathological stages such as chronic strain or acute sprain, forms multi-target intervention in the aspects of improving microcirculation, relieving pain, eliminating swelling and the like, and has a wide application prospect. And compared with the traditional plaster, the plaster better meets the requirement of modern clinic on precise treatment.

The invention provides a core prescription mining method and system based on improved association and composite clustering, and relates to the technical field of data processing, and the method comprises the steps: carrying out the statistics of the frequency of traditional Chinese medicines in a standardized traditional Chinese medicine data set; calculating a four-degree association rule analysis index of the binary drug group according to the co-occurrence frequency of the binary drug group; in combination with a preset four-degree association rule analysis index threshold value, screening out a plurality of strongly associated binary drug groups from the binary drug groups; performing standardization and vectorization processing on each strong correlation binary drug group, and constructing structured data containing channel tropism attributes and efficacy attributes; clustering the structured data through a four-order chain type composite clustering algorithm, and determining an extended cluster structure; in combination with a traditional Chinese medicine constraint theory, correcting the extended cluster structure, and outputting a traditional Chinese medicine constraint clustering result; and according to a preset core drug screening rule, optimizing the traditional Chinese medicine constraint clustering result, and generating a hierarchical core prescription structure comprising a core layer, an association layer and a special layer.

The invention belongs to the technical field of medicines. The invention relates to a plaster, in particular to a plaster containing anilinoprofen and a composition. The invention provides an externally applied medicine containing anilinoprofen or a composition containing anilinoprofen and iguratimod. Pharmacodynamic studies show that the aniline-ibuprofen single-prescription plaster can treat osteoarthritis (OA) and rheumatoid arthritis (RA), can effectively inhibit arthrocele and volume increase, remarkably reduces the level of proinflammatory factors, and improves the pathological score of joint tissue. After the anilinoprofen and the iguratimod are combined for use, the curative effect is further enhanced, multiple indexes are obviously superior to those of a single drug group, and an obvious synergistic interaction effect is shown. The iguratimod and anilinoprofen compound preparation disclosed by the invention is developed in an external form such as a gel plaster for the first time, an external compound system of anilinoprofen and iguratimod is innovatively constructed, a safe, effective and convenient novel local treatment choice is provided for OA / RA patients, especially people with oral taboo or needing long-term treatment, and the iguratimod and anilinoprofen compound preparation has good clinical transformation potential and application value.

Provided herein are linkers, linker-drug groups, and antibody-drug conjugates comprising hydrophilic groups.

The application discloses a pancreatic cancer immunotherapy drug composition for jointly targeting CD96 and PD-1, relates to the technical field of biological medicine, and comprises an anti-human CD96 blocking antibody and an anti-human PD-1 blocking antibody. By jointly blocking the double immune checkpoints of CD96 and PD-1, the pancreatic cancer immunotherapy drug composition presents a significant synergistic effect compared with single antibody treatment, can effectively enhance the killing activity of T cells on pancreatic cancer cells, reverses the immune suppression microenvironment of pancreatic cancer, and restores the anti-tumor immune response of the body. The in-vivo experimental results show that the drug composition can significantly inhibit the growth of transplanted tumors, reduce the tumor volume and the tumor weight, and the tumor inhibition effect is obviously better than that of a single drug group. The preparation has stable properties and simple administration, and provides a safe and effective new immunotherapy scheme with a conversion application prospect for clinically refractory pancreatic cancer.

The invention discloses preparation and application of a ternary carrier-free injectable hydrogel formed by co-assembling glycyrrhizic acid, norcantharidin and metal copper ions. The hydrogel can form gel under the condition of not adding auxiliary materials, has excellent gel material properties such as injectability, heat sensitivity and stability, and can be used as an ideal anti-tumor drug to be clinically applied. The hydrogel has the effects of inducing tumor cell apoptosis and copper death and resisting inflammation, and cooperatively regulates and controls a tumor microenvironment; and laser irradiation is combined to assist in enhancing the Fenton-like effect, so that chemical kinetic treatment of tumors is realized. In a Hepa1-6 tumor-bearing liver cancer mouse model, the hydrogel has an excellent anti-tumor effect, and the drug effect is obviously superior to that of each monomer drug group. In addition, the hydrogel has good biocompatibility, and is a novel anti-tumor hydrogel which is simple to prepare, green and has clinical transformation potential.

The invention discloses a pharmaceutical composition containing radix astragali, radix salviae miltiorrhizae, radix salviae miltiorrhizae and fructus schizandrae and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the pharmaceutical composition containing radix astragali, radix salviae miltiorrhizae, radix salviae miltiorrhizae and fructus schizandrae is prepared from the following raw materials in parts by weight: 30-50 parts of radix astragali, 15-30 parts of radix salviae miltiorrhizae, 15-30 parts of radix codonopsis, 15-30 parts of radix pseudostellariae, 3-5 parts of fructus schizandrae and 10-15 parts of radix et rhizoma rhei. Preferably, the oral medicine dosage forms capable of being prepared comprise hard capsules, tablets and granules. According to the application disclosed by the invention, the expression levels of p38MAPK, JNK and ERK proteins, c-fos mRNA and c-jun mRNA of myocardial tissues of rats in a medicine group are lowest, so that the medicine disclosed by the invention can be used for inhibiting the activity of an MAPK signal channel of the myocardial tissues and inhibiting the expression of related protooncogenes c-fos and c-jun so as to inhibit myocardial fibrosis. Therefore, the medicine can effectively improve the cardiac function of a DCM model rat and relieve myocardial damage, and the effect of the medicine is related to inhibition of MAPK signal channel activity.

The invention relates to a method for establishing a blood-brain barrier organ aging model and an intervention method for the model, and the method comprises the following steps: S1, model preparation: preparing cryopreserved brain microvascular endothelial cells, resuscitating the cryopreserved brain microvascular endothelial cells, preparing a culture bottle containing a culture medium for later use, preparing a culture chip and an inducer, and treating the culture chip and the inducer for later use; s2, cell culture: taking the recovered brain microvascular endothelial cells in S1, inoculating the brain microvascular endothelial cells in a culture bottle, culturing and carrying out cell passage to obtain brain microvascular endothelial cells in a logarithmic phase; s3, constructing a blood-brain barrier, inoculating the brain microvascular endothelial cells in the logarithmic phase obtained in the S2 to a chip, and culturing to obtain a blood-brain barrier model; and S4, constructing an aging model, taking the blood-brain barrier model in S3, and performing injury treatment to obtain the blood-brain barrier organ aging model. A D-galactose drug group is used for successfully inducing the aging injury of the blood-brain barrier organ model, and a reliable in-vitro blood-brain barrier organ aging injury model is provided.

The invention discloses a dampness-clearing sleep-aiding Tibetan foot bathing tablet and a preparation method thereof, and relates to the technical field of traditional Chinese medicine preparations, the dampness-clearing sleep-aiding Tibetan foot bathing tablet is composed of a monarch drug group, a ministerial drug group, an adjuvant drug group, a conductant drug group and an auxiliary material group, and the preparation method comprises the following steps: step 1, crushing; step 2, weighing; step 3, extracting active ingredients; step 4, drying and powdering; step 5, total mixing; step 6, tabletting; step 7, inner packaging; and step 8, external packaging. Through the compatibility of monarch, minister, assistant and guide, the synergistic effect of dampness clearing and sleep aiding is realized, the monarch drug group and the adjuvant drug group synergistically regulate a dampness clearing pathway (AQP4 aquaporin + TRPV1 ion channel), the minister drug group and the guide drug group synergistically enhance the sleep aiding effect (GABA receptor activation + glutamic acid inhibition), and clinical experiments show that after the traditional Chinese medicine composition is used for 4 weeks, the effective rate of improving the dampness symptom reaches 80%, and the curative effect is good. And the sleep quality improvement rate reaches 82%.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

The present application relates to the technical field of biological medicine, and in particular to a pharmaceutical composition for treating hepatocellular carcinoma and application thereof, wherein the pharmaceutical composition comprises metformin or a pharmaceutically acceptable salt thereof and obeticholic acid or a pharmaceutically acceptable salt thereof, and the weight ratio of the metformin to the obeticholic acid is 1:0.05-0.2. It is found for the first time that the combination of metformin and farnesol X receptor agonist can regulate the AMPK / mTOR pathway and the immune recruitment mediated by CXCL16 in a synergistic manner, inhibit the proliferation of tumor cells, repair the recruitment function of NKT cells in the microenvironment of hepatocellular carcinoma, and realize the dual anti-tumor effect of metabolic inhibition and immune enhancement. Animal experiments show that the tumor inhibition rate of the combination drug group is significantly better than that of the single drug group, and the safety is good.

The invention discloses a use of a mulberry (Morus alba L.) extract, including a method for treating ulcerative colitis, a method for preventing ulcerative colitis, and a method for reduction in Disease Activity Index, DAI. The use is application of a mulberry extract to the preparation of a product for treating and / or preventing ulcerative colitis. The invention experimentally demonstrated that positive drug group, SZ-A-1, SZ-A-2, SZ-A-3, SZ-A-4 and SZ-A-5 (pretreatment) could each significantly inhibit colonic atrophy in UC model mice, and the effects in SZ-A-2, SZ-A-3 and SZ-A-4 groups are comparable to that in positive drug group, with SZ-A-5 (pretreatment) achieving a superior effect to the positive drug. The mulberry extract of the invention, as a component derived from natural plants, has unique advantages of small toxic and side effects, mild and lasting actions etc.

The invention discloses a method for researching the influence of aerobic exercise on spontaneous hypertensive rat ferroptosis, and relates to the technical field of medical research. Comprising the following steps: S1, experimental animals and grouping; normal rats WKY and spontaneously hypertensive rats SHR are randomly divided into a quiet WKY control group, a quiet SHR control group, an exercise group and an exercise drug group; s2, performing aerobic exercise intervention. The research method provided by the invention verifies the assumption that aerobic movement possibly inhibits ferroptosis and hinders further development of chronic kidney diseases by activating a hypertensive kidney cell systemxc- / GPX4 / GSH pathway, and provides reference for promoting subsequent further in-depth scientific research of the subject in the field. The method has positive practical value and significance in the aspect of discussing new pathogenesis and treatment strategy of hypertension.

According to the phenothiazine functional precursor, the photosensitizer and the preparation method of the phenothiazine functional precursor, halogen or thienyl is introduced into R1 and / or R2 sites of a benzophenothiazine structure to serve as heavy atoms on the basis of structure-function relationship research of benzophenothiazine site modification, generation of strong spin-orbital coupling can be promoted, and the photosensitizer has the advantages that the photosensitizer can be used as a photosensitizer; further, intersystem crossing of the phenothiazine photosensitizer from an excited singlet state (S1) to a triplet state (T1) is promoted, so that the photosensitive effects of the phenothiazine functional precursor and the corresponding phenothiazine photosensitizer are effectively improved. Besides, after the phenothiazine photosensitizer is modified by adding a tetrazine group, controllable closing and opening of phenothiazine are realized, so that the dark toxicity of phenothiazine is effectively reduced, the targeting property and the treatment effect of the photosensitizer are improved by accessing a targeting group and a drug group into the phenothiazine photosensitizer, and the phenothiazine photosensitizer has a wide application prospect.

Provided herein are linkers comprising a hydrophilic group, linker-drug groups, and antibody-drug conjugates.

The invention discloses laurel essential oil with anti-aging activity and application of the laurel essential oil. According to the method, laurel essential oil is used for acting on caenorhabditis elegans to verify the aging delaying effect of the caenorhabditis elegans, after the caenorhabditis elegans are counted and subjected to synchronization treatment, a life determination test of the caenorhabditis elegans is carried out, a blank control group, a DMSO solvent group, a positive drug group and a laurel essential oil experimental group are set respectively, a survival curve is drawn, and statistical analysis is carried out. Results show that the lifetime of nematodes in a laurel essential oil treatment group is remarkably prolonged, and the anti-aging effect of the laurel essential oil treatment group is superior to that of a Meanwhile, target function analysis on the laurel essential oil shows that the essential oil regulates and controls senescence-related pathways. The further determination of the effect of monomer components in the laurel essential oil on delaying caenorhabditis elegans aging shows that p-cymene, methyleugenol, ocimene, linalool, sabinene, 4-terpene alcohol, terpinene and linalyl acetate show significant anti-aging activity.

The invention belongs to the technical field of microorganisms, and particularly relates to rhizobium exopolysaccharide and application thereof. By extracting and purifying the rhizobium extracellular polysaccharide and analyzing the yield and monosaccharide composition of the extracellular polysaccharide, the apoptosis action mechanism of the extracellular polysaccharide on the in-vitro liver cancer cell Hep-G2 is systematically researched. A mouse liver cancer model is constructed, a model group is used as a negative control, a specific drug group is used as a positive control, the liver cancer mouse model adopts concentration gradient exopolysaccharide intragastric administration as an experimental group, and the transcriptomics influence of the exopolysaccharide on liver cancer nude mouse blood and tumor samples is analyzed. The action effect of the exopolysaccharide in a Hep-G2 subcutaneous model is comprehensively characterized by various means such as liver and kidney toxicity test, Elisa experiment, HE staining and immunohistochemical experiment, and the regulation mechanism of the exopolysaccharide on nude mouse liver cancer tumor key protein is detected by adopting Western blot experiment.

This invention relates to a specific chimeric antigen receptor (CAR) based on a fully human anti-DLL3 single-chain antibody and its applications. The CAR comprises a CD8 signal peptide, a fully human single-chain antibody specific to the human DLL3 antigen, a CD8 transmembrane region, and 41BB and CD3ζ intracellular signal transduction domains sequentially connected in series. This invention provides immune cells modified with a human DLL3 chimeric antigen receptor by constructing and screening different DLL3 antigen-specific humanized single-chain antibodies, which can specifically bind to the human DLL3 antigen. In in vitro and in vivo killing experiments on human DLL3 antigen-positive tumor models, the CAR-T cells targeting the human DLL3 antigen of this invention significantly and specifically killed human DLL3-positive small cell lung cancer (SCLC) cell lines. Animal model experiments show that after administration of the preferred DLL3 CAR-T cells of this invention, the various drug groups showed significant efficacy, with tumor inhibition rates ranging from 25% to 97%.

The application relates to the field of medicine, in particular to the application of 4-hydroxyphenylacetic acid and irinotecan as cancer chemotherapy drugs. In view of the technical defects that the existing irinotecan chemotherapy hepatoprotective drugs have single action and may interfere with the chemotherapy effect, the application provides the application of 4-hydroxyphenylacetic acid and irinotecan in the preparation of cancer chemotherapy drugs. The application has the following advantages: 1. clear hepatoprotective effect: 4HPAA can significantly alleviate the liver fatty degeneration induced by irinotecan; 2. significant synergistic anti-tumor effect: the tumor inhibition effect of the combination of 4HPAA and irinotecan is significantly better than that of the single-drug group; 3. high safety; and 4. great clinical transformation potential.

The invention relates to the technical field of information visualization and visual analysis, and discloses a graph neural network-oriented prediction result interpretation visualization method, which comprises the following steps: acquiring and processing drug and protein related data, converting the data into a knowledge graph form, and storing the data in a graph database; performing view design, including a projection-based drug aggregation view, a drug target view, a directed acyclic graph-based drug action path view, a path comparison view and a multi-panel-based drug grouping result view, and performing visual layout and implementation respectively. According to the method, in visualization of drug interaction prediction, important features influencing model prediction can be identified, and an interaction path between drugs and a potential biological mechanism thereof are further disclosed, so that the defect that an existing method is insufficient in interpretation capability is overcome; and by constructing an interactive visual view, the credibility of the user on the model prediction result is improved.

The invention provides a pharmaceutical analysis method based on biomics and application, and belongs to the technical field of medical analysis. Comprising the following steps: S1, experiment grouping: screening participants according to a preset grouping standard, and randomly dividing the participants into a medicine group and a placebo group; s2, experimental process and sample collection: collecting detection samples of the drug group and the placebo group at three time nodes, namely before medication, during the experiment and after the experiment; s3, sample analysis; and S4, analyzing a metabolic pathway where the drug plays a role, and enriching metabolites and drug target genes. Through specific standard component grouping, sample collection in a preset stage and multi-omics comprehensive analysis, metabonomics and transcriptomics combined analysis is carried out on each experimental group, metabolism and transcription co-enrichment pathways are screened, and then metabolic pathways, enriched metabolites and drug target genes in which drugs play roles, and interaction relationships are analyzed. The potential mechanism of the medicine playing a role in relieving diseases is analyzed through a multi-omics combined technology, and reference is provided for follow-up medicine development and application.

The present application relates to the technical field of intelligent control of veterinary drug storage, and discloses a veterinary drug shelf life intelligent early warning control method and system, the method comprising: collecting the real-time storage environment of the target veterinary drug, synchronously monitoring the health abnormal state of livestock and poultry in the target farm; matching the standard storage environment of the veterinary drug, calculating the environmental deviation, and dynamically adjusting the veterinary drug shelf life warning time accordingly; combining the veterinary drug emergency consumption rate corresponding to the health abnormality of the farm, and secondarily optimizing to obtain the emergency warning time. At the same time, the historical use records of the veterinary drug are called, the associated drug group with the highest compatibility and use frequency is screened, the coordination warning time is calculated based on the emergency warning time; the near-expiration drug is selected from the drug group, the drug distribution control is carried out combined with the warehouse location data and the remaining warning time, and the coordination warning time of the associated drug group is updated in real time according to the distribution result. The present application solves the industry problems of low precision of existing veterinary drug shelf life static warning, lack of drug collaborative control, and disconnection of storage and distribution.

The invention discloses a fatty acid chain for modifying a GLP-1 / GIP / glucagon receptor stimulant and application thereof, the fatty acid chain is used for modifying the receptor stimulant by improving the aspects of the carbon chain length, the functional group type and the like of the fatty acid chain, the treatment effect of the receptor stimulant on the aspects of reducing blood sugar and reducing body weight is remarkably improved, and the fatty acid chain can be used for modifying the GLP-1 / GIP / glucagon receptor stimulant. The fatty acid chain and the receptor agonist modified by the fatty acid chain can reduce the blood sugar level and improve the sugar tolerance; meanwhile, the effects of controlling appetite, ingestion and calorie intake, increasing energy consumption, preventing weight gain, promoting weight loss and reducing overweight are achieved; in addition, the fatty acid chain and the receptor agonist modified by the fatty acid chain have a long half-life period, and the action time of drugs in vivo can be effectively prolonged.

The invention relates to the technical field of functional food, and discloses liqueur capable of regulating spleen and stomach, benefiting qi and nourishing blood and a preparation method of the liqueur. The liqueur is prepared from the following raw materials in parts by weight: 25-40 parts of a monarch drug group; 20-35 parts of a ministerial drug group; 15-25 parts of an adjuvant group; 5-10 parts of a conductant drug group; 10-20 parts of a flavor raw material group; 800 to 1500 parts of main body base liquor; the biotransformation strain is added according to 1-3% of the dry weight of the raw materials of the monarch drug group. Firstly, raw materials of the monarch drug group are subjected to biotransformation treatment; performing graded synergistic extraction according to properties of different raw materials to obtain functional mother liquor, blended mother liquor and flavor base liquor; and finally, stably fusing the functional mother liquor and the blended mother liquor with the main base liquor, and aging to obtain a finished product. According to the invention, the bioavailability of core functional components is improved through biotransformation, the physical stability of the product is improved through fractional extraction and step-by-step fusion processes, and the wine body is harmonious in flavor and excellent in sensory quality.